Ponsus Pharma strengthens its staff

Published on Thursday, 22 October 2009 00:00

By Lars Blak
Dated: Sep 29, 2009

Ponsus Pharma recruits Mats Silvander, Ph.D. as Research & Development Manager and Dan Johansson, M.Sc. as Sales & Marketing Manager

STOCKHOLM, Ponsus Pharma has appointed Mats Silvander, Ph.D. as the new Research & Development
Manager. His main area of focus will be to further develop the patented Proderm Technology®
pharmaceutical product lines. Until recently Silvander was Vice President of Product Development of
Quinnova Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and
commercialization of prescription drug products based on innovative topical drug delivery platforms. He
has a strong record of bringing to market products of large customer value.

“I am glad to be part of the Ponsus team. The prospects for the advanced topical products such as the
Proderm line are truly great. We will continue to meet our customers’ needs of modern topical products
based on high quality innovations,” Silvander says.

Also, Dan Johansson, M.Sc. was named Sales and Marketing Manager. His most recent position was
Global Product Specialist for Dako A/S managing their portfolio of concentrated antibodies.

“I see a great potential in the Proderm Technology. It is very rewarding to develop high quality products
for our customers. I see that there is a need for pharmaceutical products that the customers actually use
instead of just putting it in storage, and which increases consumer compliance”, says Johansson.

“Ponsus Pharma has been working along with Quinnova Pharmaceuticals, Inc. to successfully launch
prescription pharmaceutical products based on Proderm Technology, in the U.S. and now we are looking
for the ideal partner for a European collaboration. The addition of Mats and Dan to the Ponsus Pharma team
will allow us to move forward towards our goal of EU market acceptance for Proderm Technology” stated
Lars Blak, CEO of Ponsus Pharma.

Ponsus Pharma AB develops high performing dermatological products based on their patented Proderm Technology for pharmaceutical and cosmeceutical companies, targeting the fast moving Consumer Goods market. The water-lipid nature of the Proderm Technology allows ingredients to be rapidly absorbed and incorporated into the outer layers of the skin. Furthermore, Proderm Technology is non-comedogenic and provides a cosmetically elegant feel in addition to ease of application because it is non-greasy and spreads easily. Unlike some topical foam preparations, Proderm Technology does not use either alcohol or other organic solvents, therefore it is well tolerated by patients. Ponsus Pharma markets their products mainly through a group of marketing partners in various countries.